TY - JOUR T1 - Early Emergence and Long-Term Persistence of HIV-Infected T Cell Clones in Children JF - bioRxiv DO - 10.1101/2020.09.15.298406 SP - 2020.09.15.298406 AU - Michael J. Bale AU - Mary Grace Katusiime AU - Daria Wells AU - Xiaolin Wu AU - Jonathan Spindler AU - Elias K. Halvas AU - Joshua C. Cyktor AU - Ann Wiegand AU - Wei Shao AU - Mark F. Cotton AU - Stephen H. Hughes AU - John W. Mellors AU - John M. Coffin AU - Gert U. Van Zyl AU - Mary F. Kearney Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/09/15/2020.09.15.298406.abstract N2 - Little is known about the emergence and persistence of HIV-infected T cell clones in perinatally-infected children. We analyzed peripheral blood mononuclear cells for clonal expansion in 11 children who initiated antiretroviral therapy (ART) between 1.8-17.4 months of age and with viremia suppressed for 6-9 years. We obtained 8,662 HIV-1 integration sites from pre-ART and 1,861 sites on ART. Expanded clones of infected cells were detected pre-ART in 10/11 children. In 8 children, infected cell clones detected pre-ART persisted for 6-9 years on ART. A comparison of integration sites in the samples obtained on ART with healthy donor PBMC infected ex-vivo showed selection for cells with proviruses integrated in BACH2 and STAT5B. Our analyses indicate that, despite marked differences in T cell composition and dynamics between children and adults, HIV-infected cell clones are established early in children, persist for up to 9 years on ART, and can be driven by proviral integration in proto-oncogenes.Competing Interest StatementJWM is a consultant to Gilead Sciences, Accelevir Diagnostics, Merck, and Infectious Disease Connect. He has received grants from Gilead Sciences to the University of Pittsburgh and owns shares in Co-crystal Pharmaceuticals, Inc. and Abound Bio, Inc. The remaining authors declare no conflicts of interest ER -